US EditionTHX Pharma and Biocodex Announce a Strategic Licensing Agreement in Batten, Gaucher and Niemann-Pick Type C Diseases
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
French biopharma duo THX Pharma and Biocodex strike rare diseases licensing deal worth up to €173M - European Biotechnology Magazine
French biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet need. French biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet need.
https://www.tradingsat.com/thx-pharma-ex-theranexus-FR0013286259/actualites/thx-pharma-ex-theranexus-grace-a-un-accord-de-licences-with-the-laboratoire-francais-biocodex-for-two-s-candidates-medications-thx-pharma-flambe-de-60-en-bourse-1156339.html
pharmaceutical-technology.com
Pharmaceutical Business reviewTHX Pharma, Biocodex sign licensing deal for Batten-1 and TX01 drugs
THX Pharma and Biocodex have entered into a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type C rare diseases.
Nicolas Coudourier, Director General of Biocodex, sees it as an "example of sovereignty in France". His family group, positioned in medicines, care products and food supplements, has just concluded a major agreement with the biotech lyonnaise THX Pharma, specialist in rare neurological diseases. Agreement on the licensing of two medicinal candidates in the field of rare pathologies, with a potential of 173 million euros.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
